These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 14746589)

  • 41. Variation in Number of Doses, Bottle Volume, and Calculated Yearly Cost of Generic and Branded Latanoprost for Glaucoma.
    Queen JH; Feldman RM; Lee DA
    Am J Ophthalmol; 2016 Mar; 163():70-74.e1. PubMed ID: 26596398
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Timogel® vs timolol 0.5% ophthalmic solution: efficacy, safety, and acceptance.
    Rolle T; Curto D; Alovisi C; Franzone M; Brogliatti B; Grignolo FM
    Eur J Ophthalmol; 2012; 22(1):28-33. PubMed ID: 22167540
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Co-delivery of timolol and hyaluronic acid from semi-circular ring-implanted contact lenses for the treatment of glaucoma: in vitro and in vivo evaluation.
    Desai AR; Maulvi FA; Pandya MM; Ranch KM; Vyas BA; Shah SA; Shah DO
    Biomater Sci; 2018 May; 6(6):1580-1591. PubMed ID: 29708242
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension.
    Netland PA; Landry T; Sullivan EK; Andrew R; Silver L; Weiner A; Mallick S; Dickerson J; Bergamini MV; Robertson SM; Davis AA;
    Am J Ophthalmol; 2001 Oct; 132(4):472-84. PubMed ID: 11589866
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Dosage variability of topical ocular hypotensive products: a densitometric assessment.
    Gaynes BI; Singa RM; Cao Y
    J Glaucoma; 2009 Feb; 18(2):149-52. PubMed ID: 19225353
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effect of Proview self-tonometry on pharmaceutical compliance.
    Lievens CW; Gunvant P; Newman J; Gerstner M; Simpson C
    Clin Exp Optom; 2006 Nov; 89(6):381-5. PubMed ID: 17026606
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparison of the ocular hypotensive effect of brimonidine, dorzolamide, latanoprost, or artificial tears added to timolol in glaucomatous monkey eyes.
    Wang RF; Serle JB; Gagliuso DJ; Podos SM
    J Glaucoma; 2000 Dec; 9(6):458-62. PubMed ID: 11131752
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Evaluation of microbial contamination of canine plasma eyedropper bottles following clinical use in canine patients.
    Strauss RA; Genschel U; Allbaugh RA; Sebbag L; Ben-Shlomo G
    Vet Ophthalmol; 2019 May; 22(3):222-228. PubMed ID: 29797413
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Ocular hypotensive effects and safety over 3 months of switching from an unfixed combination to latanoprost 0.005%/timolol maleate 0.5% fixed combination.
    Inoue K; Okayama R; Higa R; Sawada H; Wakakura M; Tomita G
    J Ocul Pharmacol Ther; 2011 Dec; 27(6):581-7. PubMed ID: 22011049
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Efficacy and tolerability of timolol maleate ophthalmic gel-forming solution versus timolol ophthalmic solution in adults with open-angle glaucoma or ocular hypertension: a six-month, double-masked, multicenter study.
    Shedden A; Laurence J; Tipping R;
    Clin Ther; 2001 Mar; 23(3):440-50. PubMed ID: 11318078
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Evaluation of eye drop administration technique in patients with glaucoma or ocular hypertension.
    Schwartz GF; Hollander DA; Williams JM
    Curr Med Res Opin; 2013 Nov; 29(11):1515-22. PubMed ID: 24006861
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Patient preference, efficacy, and compliance with timolol maleate ophthalmic gel-forming solution versus timolol maleate ophthalmic solution in patients with ocular hypertension or open-angle glaucoma.
    Schenker H; Maloney S; Liss C; Gormley G; Hartenbaum D
    Clin Ther; 1999 Jan; 21(1):138-47. PubMed ID: 10090431
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A comparison of morning and evening instillation of a combination travoprost 0.004%/timolol 0.5% ophthalmic solution.
    Denis P; Andrew R; Wells D; Friren B
    Eur J Ophthalmol; 2006; 16(3):407-15. PubMed ID: 16761242
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Rapid and selective removal of preservative from ophthalmic formulations during eyedrops instillation.
    Hsu KH; Chauhan A
    Eur J Pharm Biopharm; 2015 Nov; 97(Pt A):30-8. PubMed ID: 26459089
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Fixed topical combinations in glaucomatous patients and ocular discomfort.
    Nebbioso M; Evangelista M; Librando A; Di Blasio D; Pescosolido N
    Expert Opin Pharmacother; 2012 Sep; 13(13):1829-35. PubMed ID: 22770575
    [TBL] [Abstract][Full Text] [Related]  

  • 56. In vitro and in vivo evaluation of novel implantation technology in hydrogel contact lenses for controlled drug delivery.
    Maulvi FA; Lakdawala DH; Shaikh AA; Desai AR; Choksi HH; Vaidya RJ; Ranch KM; Koli AR; Vyas BA; Shah DO
    J Control Release; 2016 Mar; 226():47-56. PubMed ID: 26860285
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The role of hyaluronan as a drug carrier to enhance the bioavailability of extended release ophthalmic formulations. Hyaluronan-timolol ionic complexes as a model case.
    Battistini FD; Tártara LI; Boiero C; Guzmán ML; Luciani-Giaccobbe LC; Palma SD; Allemandi DA; Manzo RH; Olivera ME
    Eur J Pharm Sci; 2017 Jul; 105():188-194. PubMed ID: 28506871
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Reliability of drop size from multi-dose eye drop bottles: is it cause for concern?
    German EJ; Hurst MA; Wood D
    Eye (Lond); 1999; 13 ( Pt 1)():93-100. PubMed ID: 10396391
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Six-month comparison of bimatoprost once-daily and twice-daily with timolol twice-daily in patients with elevated intraocular pressure.
    Sherwood M; Brandt J;
    Surv Ophthalmol; 2001 May; 45 Suppl 4():S361-8. PubMed ID: 11434939
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A 3-month randomized controlled trial of bimatoprost (LUMIGAN) versus combined timolol and dorzolamide (Cosopt) in patients with glaucoma or ocular hypertension.
    Coleman AL; Lerner F; Bernstein P; Whitcup SM
    Ophthalmology; 2003 Dec; 110(12):2362-8. PubMed ID: 14644719
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.